GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » PS Ratio

NRXP (NRX Pharmaceuticals) PS Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NRX Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NRX Pharmaceuticals's share price is $1.20. NRX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, NRX Pharmaceuticals's PS Ratio for today is .

The historical rank and industry rank for NRX Pharmaceuticals's PS Ratio or its related term are showing as below:

During the past 4 years, NRX Pharmaceuticals's highest PS Ratio was 12.41. The lowest was 0.00. And the median was 0.00.

NRXP's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.69
* Ranked among companies with meaningful PS Ratio only.

NRX Pharmaceuticals's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Back to Basics: PS Ratio


NRX Pharmaceuticals PS Ratio Historical Data

The historical data trend for NRX Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals PS Ratio Chart

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - -

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NRX Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, NRX Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's PS Ratio falls into.



NRX Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

NRX Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.20/0
=

NRX Pharmaceuticals's Share Price of today is $1.20.
NRX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


NRX Pharmaceuticals  (NAS:NRXP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


NRX Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Executives
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz director C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Jonathan C Javitt director, 10 percent owner, officer: Chief Scientist 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard director, officer: Chief Executive Officer 1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt 10 percent owner 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg officer: Chief Financial Officer C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof officer: Chief Comm. & Patient Officer 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault officer: General Counsel & Secretary 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster director C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
Sharon Glied director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Ackerman director, 10 percent owner, officer: President & CEO 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Big Rock Partners Sponsor, Llc 10 percent owner 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483

NRX Pharmaceuticals Headlines